.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Fish and Richardson
Express Scripts
Federal Trade Commission
Merck
Citi
Accenture
Queensland Health
UBS
Teva

Generated: September 21, 2017

DrugPatentWatch Database Preview

AVYCAZ Drug Profile

« Back to Dashboard

Which patents cover Avycaz, and what generic Avycaz alternatives are available?

Avycaz is a drug marketed by Cerexa and is included in one NDA. There are eight patents protecting this drug.

This drug has one hundred and forty-nine patent family members in fifty-two countries.

The generic ingredient in AVYCAZ is avibactam sodium; ceftazidime. One supplier is listed for this compound. Additional details are available on the avibactam sodium; ceftazidime profile page.

Summary for Tradename: AVYCAZ

Patents:8
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list2
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:AVYCAZ at DailyMed

Pharmacology for Tradename: AVYCAZ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cerexa
AVYCAZ
avibactam sodium; ceftazidime
POWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Cerexa
AVYCAZ
avibactam sodium; ceftazidime
POWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Cerexa
AVYCAZ
avibactam sodium; ceftazidime
POWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Cerexa
AVYCAZ
avibactam sodium; ceftazidime
POWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Cerexa
AVYCAZ
avibactam sodium; ceftazidime
POWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Cerexa
AVYCAZ
avibactam sodium; ceftazidime
POWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Cerexa
AVYCAZ
avibactam sodium; ceftazidime
POWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Cerexa
AVYCAZ
avibactam sodium; ceftazidime
POWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: AVYCAZ

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,638,529Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents► Subscribe
9,062,053Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-Diazabicyclo[3,2,1]octane-2-carboxamide sodium salt► Subscribe
8,829,191Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof► Subscribe
7,732,610Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents► Subscribe
9,580,424Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: AVYCAZ

Country Document Number Estimated Expiration
Hong Kong1077205► Subscribe
Brazil0307267► Subscribe
Serbia52137► Subscribe
European Patent Office2279737► Subscribe
Australia2003214335► Subscribe
Czech Republic20030223► Subscribe
Yugoslavia6303► Subscribe
Poland220725► Subscribe
Cyprus1111061► Subscribe
Norway2016024► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: AVYCAZ

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016037Lithuania► SubscribePRODUCT NAME: CEFTAZIDIMAS + AVIBAKTAMAS; REGISTRATION NO/DATE: EU/1/16/1109/001 20160624
0847Netherlands► SubscribePRODUCT NAME: FARMACEUTISCH MENGSEL OF SAMENSTEL DAT DE VOLGENDE WERKZAME BESTANDDELEN BEVAT: (1) CEFTAZIDIM OF EEN ZOUT ERVAN, EN (2) AVIBACTAM OF EEN ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/16/1109/001 20160628
2016 00059Denmark► SubscribePRODUCT NAME: FARMACEUTISK BLANDING ELLER SAMMENSAETNING DER SOM AKTIVE BESTANDDELE DERAF, HERUNDER CEFTAZIDIMPENTAHYDRAT OG AVIBACTAMNATRIUM; REG. NO/DATE: EU/1/16/1109 20160628
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Cerilliant
US Army
Chubb
Express Scripts
Boehringer Ingelheim
McKesson
Julphar
Teva
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot